SANUWAVE Health, Inc. (NASDAQ: SNWV) has added its flagship UltraMIST directed‑energy wound‑care system to Healogics iSupply, the wound‑care group purchasing organization operated by Healogics Wound Care Supply. The partnership will make UltraMIST available to Healogics members—over 600 wound‑care centers, home‑health agencies, and skilled nursing facilities—through the end of 2025, when the initial rollout is scheduled to begin.
The move extends SANUWAVE’s national reach by tapping a well‑established supply chain that already serves a broad network of providers. By entering the GPO, UltraMIST will be positioned alongside other advanced wound‑care products, accelerating adoption among hospitals and outpatient sites that rely on GPO pricing and procurement processes. The partnership is expected to boost sales volume and strengthen the company’s competitive position in the U.S. wound‑care market, which is estimated to be between $6 billion and $14 billion, not the previously cited $45 billion.
SANUWAVE’s Q3 2025 results underscore the strategic value of the partnership. Revenue rose to $11.5 million, a 22% increase from $9.4 million in Q3 2024 and a 89% jump from $6.3 million in Q3 2023. UltraMIST systems and consumables accounted for more than 97% of total revenue, and the company’s gross margin expanded to 75.5% in Q3 2024, up from 71.5% in Q3 2023. The margin growth reflects pricing power and operational leverage as the product mix shifts toward higher‑margin consumables.
Management highlighted that the Healogics partnership will accelerate market penetration and support the company’s goal of scaling UltraMIST sales. CEO Morgan Frank noted that the GPO channel “provides a trusted distribution platform that can quickly bring UltraMIST to a large, high‑volume customer base.” The partnership also aligns with SANUWAVE’s strategy to deepen relationships with key wound‑care providers and to leverage Healogics’ outcomes database to demonstrate clinical value.
Reimbursement for UltraMIST (CPT 97610) remains stable, with the 2026 Physician Fee Schedule indicating rates will be materially unchanged from 2025. This regulatory certainty supports continued adoption and mitigates pricing headwinds that have affected other wound‑care products.
While the announcement does not alter SANUWAVE’s current fiscal guidance, it signals a positive trajectory for future revenue growth and reinforces the company’s competitive moat in a market that is expanding due to rising chronic‑disease prevalence and an aging population. The partnership is expected to translate into higher sales volume and potentially higher gross margins as the company scales its distribution network.
The addition of UltraMIST to Healogics iSupply is a strategic milestone that enhances SANUWAVE’s market reach, strengthens its pricing power, and positions the company for continued growth in a sizable and evolving wound‑care market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.